Download PDF
Laryngorhinootologie 2018; 97(02): 123-137
DOI: 10.1055/s-0043-121329
Facharztwissen HNO
© Georg Thieme Verlag KG Stuttgart · New York

Aktueller Status der Therapie und Prophylaxe des Oropharynxkarzinoms

Current Status of therapy and prophylaxis of oropharyngeal carcinoma
Andreas Dietz
,
Markus Pirlich
,
Susanne Wiegand
Further Information

Publication History

Publication Date:
05 February 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Inzidenz von Oropharynxkarzinomen nimmt weltweit signifikant zu. Aufgrund ihres Zusammenhangs mit chronischem Tabak-/Alkoholkonsum, zunehmend aber auch mit dem humanen Papillomavirus HPV-16, sind die Oropharynxkarzinome eine genetisch heterogene Tumorgruppe mit hoher prognostischer Diversifikation. Dieser Beitrag versucht auf Basis der aktuellen Evidenzlage Empfehlungen zu Therapie, Prophylaxe und Früherkennung darzulegen.

Abstract

Incidence of oropharyngeal carcinoma (OPSCC) is increasing significantly worldwide. Due to its association with chronic tobacco/alcohol consumption, but increasingly also with the human papillomavirus HPV-16, oropharyngeal carcinoma is a genetically heterogeneous tumor group with high prognostic diversification. HPV-associated OPSCC respond significantly better to previous treatment concepts than non-HPV-associated. Both after primary surgical as well as after radiotherapie, radiochemotherapie and anti-EGFR treatment, this tumor group shows a significantly better survival. There is no evidence that in HPV association only primary radiotherapy concepts should be used. Currently, in the 8th edition of the TNM classification (UICC, AJCC), the HPV-associated different prognostic consideration with a rearrangement of the tumor stages and the N status was taken into account. Regardless of the known blur, p16 status detection is the most practicable and least expensive method of detection today, and is therefore consistently recommended (also by the AJCC and UICC TNM committees). HPV16 positive non-smokers differ from HPV-16 negative smokers by nearly 50 % in 5-year survival. Transoral robot surgery (TORS), which is highly acclaimed in the US today, with the Da Vinci Telemanipulator (Intuitive Surgical) has triggered a downright euphoric discussion on the minimally invasive surgery of resectable OPSCC. Based on a stable data set, it is now clear that an R0 resection must be sought regardless of the surgical procedure. Resection margins < 5 mm (R0 < 5 mm) are considered to be an “intermediate risk” situation and, like the N status, influence the adjuvant concept (radiochemotherapy). During and after transoral surgical procedures, the risk of rebleeding should never be underestimated and can not be ruled out with the utmost care.

Schlüsselwörter

Oropharynxkarzinom - Human Papilloma Virus - HPV - Transoral Robot Surgery - Radiochemotherapie - Salvage-Therapie

Key words

Oropharyngeal carcinoma - Human papilloma virus - Transoral robot surgery - Radiochemotherapy - Salvage therapy
 

  • Literatur

  • 1 Becker N, Wahrendorf J. Krebsatlas der Bundesrepublik Deutschland 1981–1990. Berlin, Heidelberg: Springer: 1998. Fortschreibung im Internet: www.krebsatlas.de
    Google Scholar
  • 2 Andl T, Kahn T, Pfuhl A. et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58 (01) 5-13
    PubMedGoogle Scholar
  • 3 Wichmann G. Variation of HPV Subtypes with Focus on HPV-Infection and Cancer in the Head and Neck Region. Recent Results Cancer Res 2017; 206: 113-122
    CrossrefPubMedGoogle Scholar
  • 4 Wagner S, Würdemann N, Hübbers C. et al. HPV-associated head and neck cancer : mutational signature and genomic aberrations. HNO 2015; 63 (11) 758-767
    CrossrefPubMedGoogle Scholar
  • 5 Wichmann G, Rosolowski M, Krohn K. et al. Leipzig Head and Neck Group (LHNG). The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 2015; 137 (12) 2846-2857
    CrossrefPubMedGoogle Scholar
  • 6 8th Edition of the UICC TNM Classification of Malignant Tumours, January 1, 2017.
    PubMedGoogle Scholar
  • 7 Boscolo-Rizzo P, Dietz A. The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de-escalate treatment regimens in p16-positive oropharyngeal cancer patients?. Int J Cancer 2017; 141 (07) 1490-1491
    CrossrefPubMedGoogle Scholar
  • 8 Golusinski W, Leemans R, Dietz A. HPV infection on head and neck cancer. Berlin, Heidelberg: Springer; 2017
    Google Scholar
  • 9 Robinson M, Schache A, Sloan P. et al. HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 2012; 6: 83-90
    CrossrefPubMedGoogle Scholar
  • 10 Smeets SJ, Hesselink AT, Speel EJ. et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-2472
    CrossrefPubMedGoogle Scholar
  • 11 Lewis Jr JS. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012; 6: 75-82
    PubMedGoogle Scholar
  • 12 Rischin D, Young RJ, Fisher R. et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148
    CrossrefPubMedGoogle Scholar
  • 13 Wasylyk B, Abecassis J, Jung AC. Identification of clinically relevant HPV-related HNSCC: in p16 should we trust?. Oral Oncol 2013; 49: e33-e37
    CrossrefPubMedGoogle Scholar
  • 14 Adelstein DJ, Ridge JA, Gillison ML. et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.. Head Neck 2009; 31: 1393-1422
    CrossrefPubMedGoogle Scholar
  • 15 Ang KK, Harris J, Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363 (01) 24-35
    CrossrefPubMedGoogle Scholar
  • 16 O’Sullivan B, Huang SH, Siu LL. et al. Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. J Clin Oncol 2013; 31 (05) 543-550
    CrossrefPubMedGoogle Scholar
  • 17 Brotherston DC, Poon I, Le T. et al. Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck 2013; 35 (02) 151-159
    CrossrefPubMedGoogle Scholar
  • 18 Weinstein GS, O‘Malley Jr BW, Magnuson JS. et al. Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope 2012; 122 (08) 1701-1707
    CrossrefPubMedGoogle Scholar
  • 19 Mattheis S, Hasskamp P, Holtmann L. et al. Flex Robotic System in transoral robotic surgery: The first 40 patients. Head Neck 2017; 39 (03) 471-475
    CrossrefPubMedGoogle Scholar
  • 20 Haughey BH, Haughey BH, Hinni ML. et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011; 33 (12) 1683-1694
    CrossrefPubMedGoogle Scholar
  • 21 Sinha P, Lewis Jr JS, Piccirillo JF. et al. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012; 118 (14) 3519-3530
    CrossrefPubMedGoogle Scholar
  • 22 Kwok P, Gleich O, Hübner G. et al. Prognostic importance of “clear versus revised margins” in oral and pharyngeal cancer. Head Neck 2010; 32 (11) 1479-1484
    CrossrefPubMedGoogle Scholar
  • 23 Wittekind C, Compton CC, Greene FL. et al. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516
    CrossrefPubMedGoogle Scholar
  • 24 Crespo AN, Chone CT, Gripp FM. et al. Role of margin status in recurrence after CO2 laser endoscopic resection of early glottic cancer. Acta Otolaryngol 2006; 126: 306-310
    CrossrefPubMedGoogle Scholar
  • 25 Meier JD, Oliver DA, Varvares MA. Surgical margin determination in head and neck oncology: current clinical practice. The results of an international american head and neck society member survey. Head Neck 2005; 27: 952-958
    CrossrefPubMedGoogle Scholar
  • 26 Slootweg PJ, Hordijk GJ, Schade Y. et al. Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncology 2002; 38: 500-503
    CrossrefPubMedGoogle Scholar
  • 27 Wittekind C. Residualtumorklassifikation in der Onkologie. Anwendungen und Probleme. Onkologe 2006; 12: 803-814
    CrossrefPubMedGoogle Scholar
  • 28 Wittekind C, Meyer HJ. TNM-Klassifikation maligner Tumoren. 7. Aufl Weinheim: Wiley-Blackwell; 2010
    Google Scholar
  • 29 Dietz A, Fischer M, Magill C. et al. Principles and New Approaches in Surgical Reconstrucion. In: Bernier J. Head and Neck Cancer. New York: Springer; 2016: 575-589
    CrossrefGoogle Scholar
  • 30 Laccourreye O, Malinvaud D, Garcia D. et al. Postoperative hemorrhage after transoral oropharyngectomy for cancer of the lateral oropharynx. Ann Otol Rhinol Laryngol 2015; 124 (05) 361-367
    CrossrefPubMedGoogle Scholar
  • 31 Salassa JR, Hinni ML, Grant DG. et al. Postoperative bleeding in transoral laser microsurgery for upper aerodigestive tract tumors. Otolaryngol Head Neck Surg 2008; 139 (03) 453-439
    CrossrefPubMedGoogle Scholar
  • 32 Pollei TR, Hinni ML, Moore EJ. et al. Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx. JAMA Otolaryngol Head Neck Surg 2013; 139 (11) 1212-1218
    CrossrefPubMedGoogle Scholar
  • 33 Robbins KT, Shaha AR, Medina JE. et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 2008; 134: 536-538
    CrossrefPubMedGoogle Scholar
  • 34 Mehanna H, Wong WL, McConkey CC. et al. PET-NECK Trial Management Group. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 2016; 374 (15) 1444-1454
    CrossrefPubMedGoogle Scholar
  • 35 Domenge C, Hill C, Lefebvre JL. et al. French Groupe d‘Etude des Tumeurs de la Tête et du Cou (GETTEC). Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 2000; 83 (12) 1594-1598
    CrossrefPubMedGoogle Scholar
  • 36 Licitra L, Grandi C, Guzzo M. et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003; 21 (02) 327-333
    CrossrefPubMedGoogle Scholar
  • 37 Zhong LP, Zhang CP, Ren GX. et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 2013; 31 (06) 744-751
    CrossrefPubMedGoogle Scholar
  • 38 Inhestern J, Schmalenberg H, Dietz A. et al. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol 2017; 28 (08) 1917-1922
    CrossrefPubMedGoogle Scholar
  • 39 Wichmann G, Krüger A, Boehm A. et al. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. Eur J Cancer 2017; 72: 144-155
    CrossrefPubMedGoogle Scholar
  • 40 Seiwert TY, Clement PM, Cupissol D. et al. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. J Clin Oncol 2010; 28 15 s (Suppl Abstr 5501)
    PubMedGoogle Scholar
  • 41 Cooper JS, Pajak TF, Forastiere AA. et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 (19) 1937-1944
    CrossrefPubMedGoogle Scholar
  • 42 Cooper JS, Zhang Q, Pajak TF. et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84 (05) 1198-1205
    CrossrefPubMedGoogle Scholar
  • 43 Bernier J, Domenge C, Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19) 1945-1952
    CrossrefPubMedGoogle Scholar
  • 44 Fietkau R, Lautenschläger C, Sauer R. et al. Postoperative concurrent radiochemotherapy versus radiotherapy in high risk SCCA of head and neck: results of the German phase III trial ARO 96–3. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24 (Suppl. 18) 5507
    PubMedGoogle Scholar
  • 45 Pignon JP, Le Maitre A, Maillard E. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NH): An update on 93 randomised trials and 17 346 patients. Radiother Oncol 2009; 92: 4-14
    CrossrefPubMedGoogle Scholar
  • 46 Budach W, Hehr T, Budach V. et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28
    CrossrefPubMedGoogle Scholar
  • 47 Nichols AC, Kneuertz PJ, Deschler DG. et al. Surgical salvage of the oropharynx after failure of organ-sparing therapy. Head Neck 2011; 33 (04) 516-524
    CrossrefPubMedGoogle Scholar
  • 48 Fakhry C, Zhang Q, Nguyen-Tan PF. et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014; 32 (30) 3365-3373
    CrossrefPubMedGoogle Scholar
  • 49 Goodwin Jr WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?. Laryngoscope 2000; 110 (3 Pt 2 Suppl 93) 1-18
    PubMedGoogle Scholar
  • 50 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
    CrossrefPubMedGoogle Scholar
  • 51 Ferris RL, Blumenschein Jr G, Fayette J. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375 (19) 1856-1867
    CrossrefPubMedGoogle Scholar
  • 52 SIKO. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen. Stand Januar 2017. Impfempfehlungen E1. 1-30
    PubMedGoogle Scholar
  • 53 Hartwig S, Syrjänen S, Dominiak-Felden G. et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012; 12: 30
    CrossrefPubMedGoogle Scholar
  • 54 D‘Souza G, Cullen K, Bowie J. et al. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 2014; 9 (01) e86023
    CrossrefPubMedGoogle Scholar
  • 55 D’Souza G, Gross ND, Pai SI. et al. Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. J Clin Oncol 2014; 32 (23) 2408-2415
    CrossrefPubMedGoogle Scholar
  • 56 Kreimer AR, Johansson M, Waterboer T. et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. Clin Oncol 2013; 31 (21) 2708-2715
    CrossrefPubMedGoogle Scholar
  • 57 Holzinger D, Wichmann G, Baboci L. et al. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer 2017; 140 (12) 2748-2757
    CrossrefPubMedGoogle Scholar